The Ad5-nCoV vaccine elicits a strong immunogenic response that lasts up to 6 months.
RBD
SARS-COV-2 INFECTION
Geometric mean titre (GMT) of serum antibodies against the RBD and SARS-CoV-2 S protein on Day 0, Day 14, Day 28 and Month 6 after vaccination measured from participants from the Ad5-nCoV (n = 371) or the Placebo group (n = 124; from the FAS for immunogenicity analysis). The GMTs with 95% CI are shown for serum antibodies against Participants that received the Ad5-nCoV vaccine exhibited a significant immunogenic response against the S protein, with antibody levels significantly increased at Day 14, Day 28 and Month 6 compared with the placebo (p<0.001; Next we examined if the antibodies offered protein against SARS-CoV-2 infection. We found that NAbs were significantly increased by Day 14 in the Ad5-nCoV group compared with levels in the Placebo group, and levels remained significantly higher at 6 Month (p<0.001; Seroconversion rates, that is, the primary analysis of the study in which the proportion of participants (out of total participants with seroconversion data) with at least four-fold increase in antibody titres after vaccination, were examined (